When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature

被引:91
作者
Talmor, Daniel [1 ]
Shapiro, Nathan
Greenberg, Dan
Stone, Patricia W.
Neumann, Peter J.
机构
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Anesthesia, Boston, MA 02215 USA
[2] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Crit Care, Boston, MA 02215 USA
[3] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pain Med, Boston, MA 02215 USA
[4] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Emergency Med, Boston, MA 02215 USA
[5] Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel
[6] Columbia Univ, New York, NY USA
[7] Tufts New England Med Ctr, Ctr Evaluat Value & Risk Hlth, Boston, MA USA
关键词
critical care medicine; intensive care unit; cost-effectiveness analysis; cost-utility analysis; quality-adjusted life years; sepsis;
D O I
10.1097/01.CCM.0000241159.18620.AB
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background. Receiving care in an intensive care unit can greatly influence patients' survival and quality of life. Such treatments can, however, be extremely resource intensive. Therefore, it is increasingly important to understand the costs and consequences associated with interventions aimed at reducing mortality and morbidity of critically ill patients. Cost-effectiveness analyses (CEAs) have become increasingly common to aid decisions about the allocation of scarce healthcare resources. Objectives., To identify published original CEAs presenting cost/quality-adjusted life year or cost/life-year ratios for treatments used in intensive care units, to summarize the results in an accessible format, and to identify areas in critical care medicine that merit further economic evaluation. Methods: We conducted a systematic search of the English-language literature for original CEAs of critical care interventions published from 1993 through 2003. We collected data on the target population, therapy or program, study results, analytic methods employed, and the cost-effectiveness ratios presented. Results. We identified 19 CEAs published through 2003 with 48 cost-effectiveness ratios pertaining to treatment of severe sepsis, acute respiratory failure, and general critical care interventions. These ratios ranged from cost saving to $958,423/quality-adjusted life year and from $1,150 to $575,054/life year gained. Many studies reported favorable cost-effectiveness profiles (i.e., below $50,000/life year or quality-adjusted life year). Conclusions: Specific interventions such as activated protein C for patients with severe sepsis have been shown to provide good value for money. However, overall there is a paucity of CEA literature on the management of the critically ill, and further high-quality CEA is needed. In particular, research should focus on costly interventions such as 24-hr intensivist availability, early goal-directed therapy, and renal replacement therapy. Recent guidelines for the conduct of CEAs in critical care may increase the number and improve the quality of future CEAs.
引用
收藏
页码:2738 / 2748
页数:11
相关论文
共 41 条
  • [1] Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis
    Angus, DC
    Linde-Zwirble, WT
    Clermont, G
    Ball, DE
    Basson, BR
    Ely, EW
    Laterre, PF
    Vincent, JL
    Bernard, G
    van Hout, B
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (01) : 1 - 11
  • [2] Angus DC, 2002, AM J RESP CRIT CARE, V165, P540
  • [3] Use of intensive care at the end of life in the United States: An epidemiologic study
    Angus, DC
    Barnato, AE
    Linde-Zwirble, WT
    Weissfeld, LA
    Watson, RS
    Rickert, T
    Rubenfeld, GD
    [J]. CRITICAL CARE MEDICINE, 2004, 32 (03) : 638 - 643
  • [4] Mechanical ventilation of patients on long-term oxygen therapy with acute exacerbations of chronic obstructive pulmonary disease:: prognosis and cost-utility analysis
    Añón, JM
    de Lorenzo, AG
    Zarazaga, A
    Gómez-Tello, V
    Garrido, G
    [J]. INTENSIVE CARE MEDICINE, 1999, 25 (05) : 452 - 457
  • [5] Trends in inpatient treatment intensity among Medicare beneficiaries at the end of life
    Barnato, AE
    McClellan, MB
    Kagay, CR
    Garber, AM
    [J]. HEALTH SERVICES RESEARCH, 2004, 39 (02) : 363 - 375
  • [6] Economic evaluation of new therapies in critical illness
    Coughlin, MT
    Angus, DC
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (01) : S7 - S16
  • [7] Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom
    Davies, A
    Ridley, S
    Hutton, J
    Chinn, C
    Barber, B
    Angus, DC
    [J]. ANAESTHESIA, 2005, 60 (02) : 155 - 162
  • [8] Systematic overview of cost-utility assessments in oncology
    Earle, CC
    Chapman, RH
    Baker, CS
    Bell, CM
    Stone, PW
    Sandberg, EA
    Neumann, PJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (18) : 3302 - 3317
  • [9] Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: A critical appraisal
    Evans C.
    Tavakoli M.
    Crawford B.
    [J]. Health Care Management Science, 2004, 7 (1) : 43 - 49
  • [10] PANCREATIC NECROSIS - ASSESSMENT OF OUTCOME RELATED TO QUALITY-OF-LIFE AND COST OF MANAGEMENT
    FENTONLEE, D
    IMRIE, CW
    [J]. BRITISH JOURNAL OF SURGERY, 1993, 80 (12) : 1579 - 1582